Aurobindo Pharma shares fell over 6% on Thursday due to an FDA inspection of Eugia-III, a formulation manufacturing facility of Eugia Pharma Specialities Ltd. The company said the inspection is ongoing and has not yet concluded. Aurobindo Pharma will inform the stock exchanges about the outcome and the number of observations after the inspection. The company has been diligently disclosing all material information as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation 2015 and confirms to disclose any material information required. The US FDA conducted an inspection at Unit VI-B, a formulation manufacturing facility in Chitkul Village, Sangareddy district, Telangana, from September 22 to September 29, 2023. The facility has now received an Establishment Inspection Report classifying it as 'Voluntary Action Indicated' (VAI).